Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

There's only one way to find out. As many here would agree, South Korea is the right next step. As others have pointed out, Japan may have been a better choice. Who knows the rationale. Either way, patient numbers are low (fact), as investors what we know is that they are going to run the trial regardless (also fact). For the longs, probably doesn't matter if the trial is stopped for low enrollment. For the shorts it might. They need to move fast on Canada and the USA.

The whole COVID thing is a risky play to begin with. Wasn't the reason I invested in them. I like the science behind the IPF data they have. But hey, if we can make something happen with COVID we will be laughing. I do believe the drug will work if they can use it on sick patients.